

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **BioMark Diagnostics Inc.** (the "Issuer").

Trading Symbol: **BUX**

Number of Outstanding Listed Securities: **106,483,435**

Date: **August 3rd, 2026**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date, and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced, and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered, nor should question be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title of each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer continued its business of developing and accelerating the commercialization of its proprietary, non-invasive, and accurate cancer diagnostic solutions, which can help detect, monitor, and assess cancer treatment early, accurately, and cost-effectively. The Company has developed its annual roadmap and continues to hold regular management meetings to discuss all aspects of the Company's business plan. It executes action items that result from these meetings.

Management's primary areas of focus continue to include:

- **Accelerating commercialization efforts of its lab-developed test (LDT) for early lung cancer detection following promising interim retrospective data presented at various oncology conferences across N. America and Europe.**
- **These results were statistically significant and continued to generate interest from leading institutions in the US, France, Germany and South America, which the company intends to pursue post-launching its assay initially in Canada following certification of its Quebec-based lab and data readout on its lung cancer clinical studies.**
- **Complete data analytics on the large-scale early lung cancer multimodal study (5,400 patients) across 7 hospitals based in Quebec after the successful completion of plasma samples and analysis using BioMark's metabolomics assay. Preliminary results from the retrospective, cancer-confirmed patient cohort, which includes an expanded non-cancer control group, have been analyzed, and the robust results met all assay performance metrics—high sensitivity and specificity. The company is discussing with key opinion leaders at the Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ) on where and when to publish the data. Additional data on the prospective lung cancer screening cohort continues to be collected in 2026 as detailed in the clinical design. Pending the outcome of the results, the company intends to present it at a major cancer symposium.**

- **Seek deeper collaborations with several high-profile USA medical institutions and introduce the company to insurance companies (payers), regulatory experts, advocacy groups, and biopharma partners as its early lung cancer LDT commercialization efforts gather momentum. The US market is strategic due to its large addressable lung cancer screening market for at-risk populations (estimated at over 16 million annually). The market remains mostly untapped as there's only a 5-6% penetration of image-based screening for the population at risk of developing lung cancer. In addition, the federal government is encouraging expanded accessibility for lung cancer screening initiatives across different states, especially for rural communities that are resource - constrained.**
 - **Continue to seek and secure the necessary funding to unlock the full potential of its diagnostic platform. The Company will continue to target non-dilutive funding opportunities from Canadian, European, and U.S. agencies and foundations to support key initiatives, including:**
 - **Optimizing our lab operations**
 - **Achieving clinical lab certification**
 - **Gathering additional real-world evidence**
 - **Embedding more AI and ML capabilities**
 - **Driving U.S. expansion and payor endorsement**
 - **Fueling business development**
 - **Conducting clinical studies to extend the platform to additional cancers and define its role in treatment response assessment**
 - **Filing patents to protect discoveries and strategically expand patent estate**
2. Provide a general overview and discussion of the activities of management.
- **Despite persistent ongoing geopolitical tensions and resulting global economic challenges, the company is strategically positioned to navigate these hurdles and capitalize on the significant opportunities within the oncology molecular diagnostics sector. Our core expertise in metabolomics and AI-driven biomarker discovery directly addresses the need for earlier (stage shifting), accessible, and more precise cancer detection. While navigating a cautious investment landscape and a rapidly evolving technology environment with a scarce talent market, the Company has proactively implemented agile strategies and resilient operational and financial systems to counteract these headwinds. Furthermore, recognizing the transformative power of technology, the**

Company is strategically building a robust AI infrastructure through key collaborations, aiming to leverage advanced analytics to enrich assay results and enhance its cancer diagnostics capabilities. The company is committed to continuous innovation and disciplined execution to realize the full potential of these opportunities for our stakeholders.

- BioMark operates within a challenging economic environment that significantly impacts small-cap diagnostic companies. The funding landscape shows recovery with continued selectivity for investment. This environment particularly challenges emerging diagnostic companies like BioMark, as investors continue to prioritize clinical-stage companies with proven concepts. Investor caution and a skilled labor shortage in bioinformatics are impacting the industry. Financing timelines are extended, making fundraising particularly challenging for small-cap diagnostic companies.
- On July 14, 2026, BioMark received the Notice of Allowance for patent application in China, titled "Method of Diagnosing Early-Stage Non-Small Cell Lung Cancer". The patented technology includes the core biomarker panel and algorithm currently incorporated into BioMark's minimally invasive blood test for the early detection of non-small cell lung cancer (NSCLC). The additional patent allowances further strengthen BioMark's global intellectual property portfolio and commercial positioning.
- On August 28, 2026, the Company conducted and successfully completed the annual audit with the auditor, MNP LLP – Audited Financial Statement and MD&A filed in SEDAR and Canadian Securities Exchange as required by regulators.
- On July 31, 2026, BioMark Diagnostics endorsed Global Call for Equitable Access to Early Screening on 2026 World Lung Cancer Day. BioMark proudly aligns with leading international healthcare organizations demanding equal access to early detection by developing simple, accessible blood testing that empowers patients and physicians with critical diagnostic insights when it matters most.

- On July 31, 2026, Manitoba Lung Association issued a news release titled “Earlier Detection. Better Outcomes. A New Manitoba Initiative Explores the Future of Lung Cancer Risk Assessment and Detection”, announced that the Manitoba Lung Association and BioMark Diagnostics are exploring whether earlier detection could improve health outcomes and ultimately save lives for people at increased environmental risk after building on years of lung cancer prevention and radon awareness. Here is the link from the Manitoba Lung Association regarding the news release: https://www.mb.lung.ca/media_features
- Following BioMark’s October 7, 2025, announcement regarding its participation in the landmark HANSE lung cancer screening trial in Germany, significant progress has been achieved. By the end of July 2026, the study successfully completed. About 7000 samples had been successfully analyzed at BioMark’s laboratory in Quebec City. Discussions with the Hanse team is planned later in September / October as some preliminary data analysis and special sample requested are analyzed if needed. The study met all key execution yardsticks, including recruitment, visit completion, biospecimen collection, imaging adherence, and end-to-end sample processing, underscoring the feasibility of implementing an advanced, risk-adapted lung cancer screening program at scale.
- BioMark’s strategic collaboration with Harrisburg University under the leadership of Dr. Maria Vaida, Assistant Professor of Data Science, along with her Ph.D. student team, created a semantic embedded deep learning framework that provides an additive predictive signal across linear, kernel based, tree based, and neural network models from blood plasma using metabolites that significantly enhances biologic assay performance and diagnostic capabilities. Several papers are in the pipeline for the submissions to relevant and important journals throughout the year. The most recent two papers titled “Smoking-Stratified Signal Decomposition and Feature Selection Improves Never-Smoker Cancer Classification in a Combined Lung–Breast Metabolomics Cohort” and “CDR-Informed Graph Neural Network for Plasma Metabolomics in Lung Cancer and Pulmonary Neuroendocrine Neoplasms” have been submitted for publication and are currently under review. Once published the link to the article will be available on the company’s website.

- University of Manitoba group led by Ted M Lakowski submitted a publication titled “Validated LC-MS/MS methods show acetyl-rimantadine is a superior biomarker of SAT1 activity compared to acetyl-amantadine for cancer applications” to the Journal of Chromatography B. Once published the link to the article will be available on the company’s website.
 - The Company has been approached by multiple international institutions and investment brokers regarding potential partnerships and licensing opportunities aligned with its commercialization strategy. While discussions remain at a preliminary stage, any material developments will be disclosed in future updates. In addition, BioMark received interest from two U.S. states exploring potential business expansion opportunities. Any substantive progress in these discussions will be announced in subsequent monthly reports.
 - BioMark continues to entertain discussions with various financial institutions, accredited individual investors, and government agencies to secure non-dilutive funding, favourable loans, and equity investments to accelerate the commercialization of its early lung cancer liquid biopsy franchise, to advance its expansion strategy in the USA and internationally as well as for general corporate purposes.
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.
- Not applicable.**
4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements, etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Not applicable.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from, or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable.

8. Describe the acquisition of new customers or loss of customers.

Not applicable.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists, and trademarks.

On July 14, 2026, BioMark received the Notice of Allowance for patent application in China, titled "Method of Diagnosing Early-Stage Non-Small Cell Lung Cancer".

The Issuer continues to file trademarks and patents in specific jurisdictions for all its patents. Review of the filings and opinions from patent offices are being reviewed as needed.

10. Report on any employee hiring, terminations or lay-offs with details of the anticipated length of lay-offs.

Not applicable.

FORM 7 – MONTHLY PROGRESS REPORT

11. Report on any labour disputes and resolutions of those disputes if applicable.
Not applicable.
12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
Not applicable.
13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
Not applicable.
14. Provide details of any securities issued and options or warrants granted.
Not applicable.
15. Provide details of any loans to or by Related Persons.
Not applicable.
16. Provide details of any changes in directors, officers, or committee members.
Not applicable.
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.
The trends and risks that are likely to impact the Issuer are discussed in the Form 51-102F1 Management's Discussion & Analysis Annual Report for the Year Ended March 31, 2026.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there where is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated August 3rd, 2026

Rashid Ahmed Maula Bux
Name of Director or Senior Officer

"Rashid Ahmed Maula Bux"
Signature

President & CEO
Official Capacity

Issuer Details Name of Issuer BioMark Diagnostics Inc.	For Month End July 31, 2026	Date of Report YY/MM/DD 2026/08/03
Issuer Address 145 - 10451 Shellbridge Way		
City/Province/Postal Code Richmond, BC, V6X 2W8	Issuer Fax No. N/A	Issuer Telephone No. (604) 370-0779
Contact Name Rashid Ahmed Bux	Contact Position CEO	Contact Telephone No. (604) 370-0779
Contact Email Address info@biomarkdiagnostics.com	Web Site Address www.biomarkdiagnostics.com	

FORM 7 – MONTHLY PROGRESS REPORT